ArticleFrontiers in immunology2024

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.

Song Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.